Trials / Completed
CompletedNCT02062190
Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia
Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Federal University of Rio Grande do Sul · Academic / Other
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?
Detailed description
Randomized, double-blind, placebo-controlled trial comparing supplementation with resveratrol or placebo in patients diagnosed with schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | resveratrol | 100mg 2x/day 1 month |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2015-01-01
- Completion
- 2015-05-01
- First posted
- 2014-02-13
- Last updated
- 2015-12-08
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT02062190. Inclusion in this directory is not an endorsement.